Navigation Links
Pharmagen Announces First Quarter 2013 Results
Date:5/15/2013

SILVER SPRING, Md., May 15, 2013 /PRNewswire/ -- Pharmagen, Inc. (OTCBB: PHRX) (the "Company" or "Pharmagen") today announced financial results for the quarter ended March 31, 2013. On a consolidated basis, revenues for the three months ended March 31, 2013 totaled $1.72 million as compared to the three months ended March 31, 2012, representing a 329% increase year-over-year.  Adjusted for nonrecurring expenses, and depreciation and amortization, the company reported a slight profit for the quarter on an EBITDA basis. The company had one-time, non-recurring expenses of approximately $340k, and amortization and depreciation of approximately $335k, representing an operating loss of $666,0000. The companies branded multivitamin Clotamin® reported first quarter sales of approximately $500,000, representing a 1,000% increase compared to the first quarter of 2012. Gross margins for the company continue to improve, expanding from 44% in the first quarter of 2012 to 60% in the first quarter of 2013. Margin improvement is being driven primarily from increased sales of Clotamin® and revenues generated by Pharmagen Laboratories. Pharmagen Wholesale's license base has expanded to 40 states and Pharmagen Laboratories has expanded to 24 states. The company is weighing a strategic move to North Carolina as it attempts to become an FDA-approved generic manufacture of sterile injectable pharmaceuticals, utilizing a revolutionary cGMP + ® process. It is seeking an incentive package from the State of North Carolina. Management continues to be the largest shareholder and retains its entire equity position since going public.

"Since the meningitis outbreak, drug shortages are now at the forefront of health policy, second only to the Affordable Care Act. Pharmagen is positioned perfectly as one of the only companies in the United States to address this problem. We've literally built our company around this issue. From a hospitals perspective, we're a one stop shop, offering secondary wholesale, state of the art compounding, and hopefully in the near future, FDA manufacturing. There isn't another company that I'm aware of that plays in all three verticals," said Mackie A. Barch , CEO of Pharmagen.

Barch went on to say, "While we still have a long way to go, we're getting better every day. Management continues to hold the largest equity position in the company, aligning us perfectly with our shareholders. Speaking for the entire management team, we only plan on adding to that position."

About Pharmagen

Pharmagen, Inc. ("Pharmagen"), and wholly owned subsidiaries and operating divisions Pharmagen Laboratories, Inc., Pharmagen Distribution, LLC and Pharmagen Nutraceuticals, Inc. is the leader in innovative solutions to the nations sterile pharmaceutical crisis. With a multifaceted approach, Pharmagen is meeting the demand of health provider market through dynamic, independent wholesale, compounding, and innovative IT solutions.  Nationally focused, Pharmagen is a dynamic distributor of specialty drugs, compounding and admix pharmacy and producer of over-the-counter ("OTC") branded multivitamins to the healthcare provider market. Pharmagen currently functions as a just-in-time source of supply for hospitals for those products that are hard-to-find due to drug manufacturers' production shortages.

Contact:  888-264-4597 or info@pharmagenrx.com

Safe Harbor Statement
Information in this document constitute forward-looking statements or statements which may be deemed or construed to be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words "forecast", "anticipate", "estimate", "project", "intend", "expect", "should", "believe", and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve, and are subject to known and unknown risks, uncertainties and other factors which could cause Pharmagen actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. The risks, uncertainties and other factors are more fully discussed in Pharmagen' filings with the U.S. Securities and Exchange Commission. All forward-looking statements attributable to Pharmagen herein are expressly qualified in their entirety by the above-mentioned cautionary statement. Pharmagen disclaims any obligation to update forward-looking statements contained in this estimate, except as may be required by law.

 


'/>"/>
SOURCE Pharmagen, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Pharmagen to Present Strategic Vision for Solving Nations Parenteral Drug Shortage Crisis at 2013 BIO International Convention
2. Pharmagen Laboratories Remains Industry Leader on Patient Safety
3. Pharmagen Presents to North Carolina General Assembly at N.C. Bios Legislative Breakfast
4. Pharmagen Announces Year-End Financial Results
5. BioDrain Announces First Quarter 2013 Results
6. International Isotopes Inc. Announces First Quarter 2013 Financial Results
7. Array BioPharma Announces Clinical Data Presentations At The 2013 ASCO Annual Meeting
8. Concord Medical Announces the Signing of US$50 Million IFC Loan Agreement
9. The Law Offices of Marc S. Henzel Announces Class Action Lawsuit Against Aveo Pharmaceuticals, Inc. and Certain Officers -- (Nasdaq: AVEO) was filed on behalf of stockholders
10. Heska Announces Financial Results for the First Quarter of Fiscal 2013
11. DEACOM ERP Announces MRO Module for Process and Mixed Mode Manufacturing Companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/17/2019)... (PRWEB) , ... July 17, 2019 , ... The American ... APNA Board of Directors and 2020 Nominating Committee . Elected by psychiatric-mental health nurse ... APNA 33rd Annual Conference in New Orleans, LA, October 2-5, 2019. , ...
(Date:7/17/2019)... ... July 17, 2019 , ... ... solution needed to attract new customers, better engage existing patients and collaborate with ... digital marketing services in tandem with an all-in-one platform. With the Updox approach, ...
(Date:7/17/2019)... LOS ANGELES (PRWEB) , ... July 17, 2019 , ... ... Angeles to reclaim their smiles with Kanani's innovated bonding procedures. Bonding is just one ... other methods, bonding can be done in a single visit, and patients leave immediately ...
Breaking Medicine Technology:
(Date:7/17/2019)... SAN DIEGO (PRWEB) , ... July 17, 2019 , ... ... not become parents. Every Intended Parents’ story differs , but, in addition to ... their Surrogate. , Across the globe, more and more Intended Parents are electing to ...
(Date:7/17/2019)... ... July 17, 2019 , ... Dr. Jonathan Zaidan, MD, FACOG, President ... WJR’s Health Woman Show. The show airs on Wednesday, July 17ths at 7pm. ... , Dr. Zaidan and co-host Ann Thomas discuss the challenges that women face when ...
(Date:7/13/2019)... , ... July 12, 2019 , ... ... YCBD), has been named a “Brand to Watch” by Brightfield Group, a leading ... cbdMD in the top 10 of domestic CBD companies in two categories, Topicals ...
(Date:7/11/2019)... ... 2019 , ... Swagelok Southeast Texas, a distributor for Ohio-based ... acquisition of another Houston-area distributor. The acquisition of the Swagelok Central Houston facility ... Nederland and Houston. , With this expansion, Swagelok Southeast Texas also extends ...
(Date:7/10/2019)... ... 10, 2019 , ... HMP, a leader in healthcare events and education, today ... Pathways Congress, taking place October 11-13, 2019 in Boston. , Launched in 2016, the ... the expansion of clinical pathways as a decision support tool and their increasing influence ...
Breaking Medicine News(10 mins):